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HIV vaccine designis considered occluded on many primary viruses. However, virus sensitivity to
neutralization by different V3 mAbs often varies, indicating that access to V3 is not restricted equally for all
antibodies. Here, we have sought to gain a better understanding of these restrictions by determining the
neutralizing activities of 7 V3 mAbs (19b, 39F, CO11, F2A3, F530, LA21, and LE311) against 15 subtype B
primary isolates and relating these activities to the ﬁne speciﬁcity of the mAbs. Not surprisingly, we found
that most mAbs neutralized the same 2–3 viruses, with only mAb F530 able to neutralize 2 additional viruses
not neutralized by the other mAbs. Epitope mapping revealed that positively-charged residues in or near the
V3 stem are important for the binding of all the mAbs and that most mAbs seem to require the Pro residue
that forms the GPGR β hairpin turn in the V3 tip for binding. Based on the mapping, we determined that V3
sequence variation accounted for neutralization resistance of approximately half the viruses tested.
Comparison of these results to those of select V3 mAbs with overall better neutralizing activities in the light
of structural information illustrates how an antibody's mode of interaction with V3, driven by contact residue
requirements, may restrict the antibody from accessing its epitope on different viruses. Based on the data we
propose an angle of interaction with V3 that is less stringent on access for antibodies with cross-neutralizing
activity compared to antibodies that neutralize relatively fewer viruses.
© 2008 Elsevier Inc. All rights reserved.IntroductionAn HIV vaccine will likely need to incorporate a component that
elicits an antibody response capable of neutralizing a broad array of
circulating virus isolates (Gallo, 2005). The target for neutralizing
antibodies (NAbs) is the viral envelope spike (Burton and Monteﬁori,
1997) and many strategies are being pursued to elicit antibodies with
the desired level of cross-neutralizing activity (reviewed in (Haynes
and Monteﬁori, 2006; Hu and Stamatatos, 2007; Phogat and Wyatt,
2007)). However, as a result of viral evolution, driven perhaps in most
part by host NAb pressure (Beaumont et al., 2001; Frost et al., 2005;
Wei et al., 2003), the envelope spike harbors a remarkable plethora of
features to shield conserved regions from antibody recognition
(reviewed in (Karlsson Hedestam et al., 2008; Wyatt et al., 1998)).
Collectively, these features represent a substantial scientiﬁc hurdle
towards formulating a NAb-inducing HIV vaccine component, as
evident from the relatively low cross-neutralizing activity of NAbs
elicited by the large majority of immunogens developed to date.l rights reserved.To aid the design of an effective B-cell immunogen, and given HIV's
defenses, the antigenicity of the functional envelope spike on different
HIV isolates from different subtypes needs to be elucidated. This
process has been aided greatly by the existence of a handful of rare
mAbs that can neutralize a broad range of primary viruses and protect
against viral challenge in animal models, which have allowed also for
the identiﬁcation of potential target sites for vaccine design (Burton
et al., 2004; Kramer et al., 2007; Zolla-Pazner, 2004). Unfortunately,
the inability to elicit NAbs with similar broad neutralizing activity or
even with modest cross-neutralizing activity suggests that there are
still gaps in our understanding of features that affect efﬁcient antibody
recognition of epitopes on the envelope spike and of how to design
immunogens to effectively elicit antibodies to target sites that have
been identiﬁed (Hu and Stamatatos, 2007).
One of the potential, albeit often debated, target sites for vaccine
design is the V3 loop on the gp120 subunit of the envelope spike
(Hartley et al., 2005; Haynes and Monteﬁori, 2006; Zolla-Pazner,
2005). The V3 loop has been studied extensively. Lower enthusiasm
for seeking to target V3 is based largely on the general observation
that V3 antibodies often exhibit poor cross-neutralizing activity
(Hartley et al., 2005) and several factors, for example steric hindrance
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V2 (Gram et al., 1994; Krachmarov et al., 2005, 2006; Pinter et al.,
2004; Schonning et al., 1996), help explain why many V3 mAbs may
exhibit little neutralizing activity. A recent study has suggested also
that the presence (or absence) of certain V3 residuesmay greatly affect
the neutralizing activity of V3 mAbs and the presence of subtype-
speciﬁc epitopes within V3 has been proposed (Patel et al., 2008).
There exists, however, a small selection of V3 mAbs that exhibit
relatively better cross-neutralizing activity than other V3 mAbs (Eda
et al., 2006; Gorny et al., 2006; Pantophlet et al., 2007). The
neutralizing activity of these select mAbs suggests that they may be
hampered less by at least some of the access-restrictive factors
outlined above. The notion that such restrictions do not apply equally
to all V3 antibodies is supported also by the often noted spectrum of
virus sensitivities to different V3 mAbs (Gorny et al., 2004, 2002).
Here, we wanted to investigate the extent to which the ﬁne
speciﬁcity of V3 mAbs affects their neutralizing activity, as part of
efforts to better comprehend the often observed resistance of HIV
isolates to V3-directed antibodies and broad antibody recognition in
general. Efforts were made in a recent study to map the epitopes of
different V3 mAbs using a phage-display peptide library expressing
random dodecamer sequences (Patel et al., 2008). However, for most
mAbs that were investigated, no consensus sequence could be
identiﬁed that resembled V3. In this study, we applied a common
scanning mutagenesis approach, utilizing a panel of V3 mutants that
previously allowed mapping, with high accuracy, of residues impor-
tant for the binding of the modestly cross-neutralizing V3 mAb B4e8
(Bell et al., 2008; Pantophlet et al., 2007).
Results
Neutralizing activity of V3 mAbs against subtype B primary viruses
To assess the cross-neutralization potential of the V3 mAbs, we
tested them against a panel of 15 viruses in a robust and highly
sensitive pseudovirus-based single-round infectivity assay with
luciferase readout (Table 1). The viruses were selected from a
previously published 30-member panel of subtype B primary viruses
(Binley et al., 2004) because they exhibit diverse sensitivities to V3
mAbs (Binley et al., 2004; Li et al., 2005). The test conditions were the
same as described in the Binley et al. study. IC50 values are reported
because they allow for a more reliable comparison between theTable 1
Neutralizing activity of V3 mAbs against a panel of subtype B viruses
a All viruses are quasispecies pools except where noted. Virus designations are gener
amphotrophic murine leukemia virus (negative control virus). c, molecular clone.
b IC50s are color-coded as follows: white, IC50N 50 μg/ml; blue, 50 μg/mlN IC50N10 μg/ml;
(447D), and 58.2 are taken from a previous studies (Binley et al., 2004; Pantophlet et al., 200
the IC50 against the molecular clone listed has not been determined.potency and cross-reactivity of different antibodies, as argued
previously (Binley et al., 2004).
Overall, the mAbs were only able to neutralize a very limited
number of viruses; most mAbs neutralized 2–3 viruses, whereas only
mAb F530 neutralized 5 viruses (Table 1). The 92BR020 molecular
clone was neutralized by all 7 mAbs and was shown previously as
neutralization-sensitive to V3 mAb B4e8 (Pantophlet et al., 2007).
Strikingly, the quasispecies pool of this virus was not neutralized by
V3 mAbs 58.2 or 447-52D (Table 1) (Binley et al., 2004), even though
the amino acid sequences of the quasispecies pool and the molecular
clone share ∼95% homology; the clone is also similarly sensitive to
neutralization by mAbs b12, 2G12, 2F5, and 4E10 and a broadly
neutralizing HIV+ serum as the quasispecies pool (T. Wrin et al.,
unpublished results). Although we cannot readily explain the
discrepancy between the quasispecies pool and the clone for mAbs
58.2 and 447-52D, the results suggest that virus 92BR020 is generally
sensitive to neutralization by V3 antibodies.
Viruses 93TH305 and 5768-p27were neutralized by 5 and 4 of the 7
mAbs tested here, respectively (Table 1). For virus 93TH305 the IC50
values ranged from 13–37 μg/ml, in the same range as observed
previously for V3 mAbs 447-52D, 58.2 and B4e8 (Table 1). For virus
5768-p27, IC50s ranged from3–41 μg/ml. Virus 5768-p27 is not sensitive
to neutralization by mAbs 447-52D, 58.2, or B4e8 (IC50sN50 μg/ml;
Table 1), most likely due to the rather uncommon Lys at position 315;
mAbs 447-52D, 58.2, andB4e8 prefer anArg at this position for efﬁcient
binding (Keller et al.,1993; Pantophlet et al., 2007; Seligmanet al.,1996;
White-Scharf et al., 1993; Zolla-Pazner et al., 2004).
Aside from viruses 92BR020, 93TH305, and 5768-p27, only mAb
F530 also neutralized viruses 91US056 and 92HT594 (Table 1). Virus
91US056 is not sensitive to neutralization bymAbs 447-52D, 58.2, and
B4e8 (Binley et al., 2004; Pantophlet et al., 2007), because of the Ala at
position 315 instead of an Arg. Virus 92HT594 is neutralized also by
mAbs 447-52D and B4e8 (IC50s: 8 and 4 μg/ml, respectively; Table 1),
but is resistant to neutralization by mAb 58.2. None of the V3 mAbs
tested here neutralized (IC50N50 μg/ml) any of the other viruses that
are neutralization-sensitive to mAbs 58.2, 447-52D, and/or B4e8
(Table 1).
MAb ﬁne speciﬁcity as determined by V3 alanine scanning
The same 18 alanine point mutants generated previously for
mapping the speciﬁcity of mAb B4e8 (Pantophlet et al., 2007) wereally denoted as year (of isolation), country (of isolation), and name/number. aMLV,
yellow, 10 μg/mlN IC50N1 μg/ml; red, IC50b1 μg/ml. The IC50s for mAbs B4e8, 447-52D
7). ⁎, IC50 obtained with quasispecies pool (mAbs 447D and 58.2 only); for these viruses
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proved highly accurate for mapping B4e8′s ﬁne speciﬁcity, as
evidenced by the interactions observed between B4e8 and V3 from
the subsequent structure of a B4e8:V3 peptide complex (Bell et al.,
2008). As with mAb B4e8, apparent antibody binding afﬁnities were
determined and related to the apparent antibody afﬁnity for wild-type
gp120 (Pantophlet et al., 2007). In general, we found that the binding
of all mAbs could be reduced by several substitutions. However, none
of the patterns resembled the effects of alanine substitutions on B4e8
binding (Table 2). We also observed that the binding of several mAbs –
19b, CO11, F2A3, F530, and LA21 – was increased upon changing
select residues to Ala; the largest number of increases was observed
with mAb F2A3 (Table 2). The following speciﬁc observations were
also made:
(a) Binding of mAb 19b was strongly reduced (N10-fold) upon
substitution of Arg304, Ile307, Pro313, Arg315, Phe317, or Tyr318, and
moderately reduced (∼4-fold) upon substitution of Lys305 (Table
2). These results are consistent overall with those from previous
mapping studies of mAb 19b utilizing Ala-substituted peptides
and various gp120s (Moore et al., 1995; Scott et al., 1990). We note
that Arg304 and Lys305, identiﬁed here as important for 19b
binding, have not been investigated in the previous Scott et al. or
Moore et al. studies. We did not ﬁnd the side chain of Thr320 to be
important for 19b binding, in agreement with results from the
Moore et al. study showing that residues with physicochemical
properties different from threonine can occupy position 320 in
phage-displayed peptides selected with mAb 19b (Moore et al.,
1995). A recent study by Patel et al. proposed Ile307, His308, Gly312,
Pro313, and Ala316 as important for mAb 19b binding, based on a
peptide sequence selected with 19b from a peptide phage display
library (Patel et al., 2008). However, this sequencewas only 1 of 10
different sequences selected and, thus, may not have been
representative of the 19b epitope. We also found that substituting
Asp325 with Ala increased the binding afﬁnity of mAb 19b by 2-
fold (Table 2). Asp325 forms a salt bridgewith Arg419 locatedwithin
the coreceptor binding site on the gp120 core (Huang et al., 2005).
This interaction may restrict the structural ﬂexibility of the C-
terminal stem of the V3 loop; introducing the Ala may prevent
formation of this salt bridge, thus, allowing for a better formation
or presentation of the 19b epitope.
(b) The apparent binding afﬁnity of mAb 39F, unlike all the other
mAbs, was diminished solely by substitutions at the juncture of
the V3 stem and tip but not by substituting residues located
central to the V3 tip, such as Pro313 or Arg315 (Table 2). Speciﬁcally,
binding afﬁnity was strongly diminished by replacing Lys305 or
Ile307 with Ala, and moderately decreased upon substitution of
Ser306 and Ile309, suggesting that this mAb interacts principallyTable 2
Epitope mapping of V3 mAbs
a Apparent afﬁnities were determined as the antibody concentration at half-maximal
Apparent afﬁnities relative to wild-type gp120JRCSF were calculated with the formula (app
binding afﬁnity; blue: N10% to b50% relative binding afﬁnity; white: N50% to b200% relati
are taken from (Pantophlet et al., 2007). Residue numbering is based on the HXB2 reference seque
of the V3 region (left to right).
b V3 is divided into 3 structural segments based on the V3 structure in the context of
326–331 (C-terminal portion)), (II) the stem (residues 301–305 (N-terminal portion) andwith the N-terminal ﬂank of the V3 loop. This notion is supported
further by the observation that substitution of Arg298 and Arg304
also diminished binding, although not substantially (Table 2).
(c) The binding of mAbs CO11, F2A3, LA21, and LE311 was diminished
by many of the same substitutions (Table 2). The apparent
afﬁnities of all four mAbs were diminished upon substitution of
His308 and binding of mAbs CO11, LA21 and LE311 was substan-
tially reduced upon substitution of Pro313. The extremely strong
reduction in the apparent binding afﬁnity of mAbs CO11 and LA21
for mutant P313A (500- and 250-fold, respectively; Table 2)
suggests that interaction with the aliphatic side chain of the Pro
and/or a precise conformation of the V3 β-hairpin turn may be
critical for efﬁcient binding of these two mAbs. The apparent
binding afﬁnities of the two other mAbs, F2A3 and LE311, for
mutant K305A were strongly diminished (N10-fold) relative to
wild-type binding. This observation suggests that the epitopes of
these two antibodies may overlap mostly with the N-terminal
ﬂank of the V3 region. It should be remarked that the residues
identiﬁed here as important for binding of mAb CO11 (His308,
Pro313, and Arg315) are consistent with the sequence proposed
recently in a Patel et al. study as the (core) epitope of mAb CO11
(Patel et al., 2008); contrary to the above-noted low frequency of
the proposed 19b epitope sequence, the CO11 sequence was
identiﬁed in 11 of 20 phage-displayed peptide sequences selected
with mAb CO11.
(d) As noted above, the binding of mAb F2A3 was substantially
enhanced by several substitutions: I309A, F317A, Y318A and
D325A (Table 2). We posit that the inﬂuence of Asp325 is the same
as postulated above for mAb 19b. Based on the projection of the
mapping results onto the gp120+V3 structure (see below), we
posit that the other 3 residues affect the precise alignment of
critical residues required for the interaction with F2A3; as with
Asp325, their interaction with neighboring residues likely affects
how well the F2A3 epitope is presented.
(e) The effects of the Ala-substitutions on mAb F530 binding were
very similar to the previous four mAbs (Table 2), which likely
explains its ability to neutralize the same viruses as the other 4
mAbs (cf. Table 1). However, unlike the other 4mAbs, the apparent
binding afﬁnity of mAb F530 was not reduced as substantially by
the His308→Ala change.
V3 mAb ﬁne speciﬁcity related to neutralizing activity
We ranked, for each mAb, the viruses that were most potently
neutralized followed by those viruses that were not neutralized, to
determine which residues are permissible (Fig. 2). Because some of
the viruses used are from quasispecies pools, we listed all variant V3binding based on ELISA binding curves using the program Graphpad Prism (v.4.0).
arent afﬁnity for wild type/apparent afﬁnity for mutants)×100%. Red: b10% relative
ve afﬁnity between; black: N200% relative afﬁnity. The mapping results for mAb B4e8
nce (http://www.hiv.lanl.gov/). The mutants are arranged from the N- to C-terminal portion
gp120 (Huang et al., 2005): (I) the base (residues 296–300 (N-terminal portion) and
321–325 (C-terminal portion)), and (III) the tip (residues 306–320).
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Fig. 2. Effects of alanine substitutions on antibody bindingmapped onto the structure of V3 in the context of gp120. Substitutions that signiﬁcantly diminished or increased binding of
the V3mAbs tested here (Table 2) weremapped onto the structure of gp120JR-FL-core with V3 attached (Huang et al., 2005); only the V3 structure is depicted (surface rendering). The
color scheme is the same as in Table 2. Molecular graphics images were produced using the UCSF Chimera package (http://www.cgl.ucsf.edu/chimera), then compiled and labeled in
Adobe Photoshop.
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viruses QH0515 and 92BR021.
Of all the mAbs tested here, only mAb 19b neutralized virus 5768-
p27 more potently than virus 92BR020 (Table 1; Fig. 1); although the
residues identiﬁed as important for 19b binding are present in the V3
sequence of both viruses, a notable difference between them is the
residue at position 309, which is a Met in virus 5768-p27 and an Ile in
virus 92BR020. It has been shown previously that consensus peptide
sequences selected with 19b from a phage-display library predomi-
nantly contain a Met at position 309 (Moore et al., 1995); thus, 19b
seems to require an aliphatic side chain at position 309, with greater
preference for Met. Based on the mapping, the inability of mAb 19b to
neutralize the 6 viruses QH0515, BG1168, 6101-p15, 91US056,
92BR021, and ME1 could be explained by substitution of important
contact residues (Fig. 1), whereas inability of themAb to neutralize the
other 6 viruses (QH0692, SS1196, 92US712, 93TH305, JR-CSF, and JR-
FL) could not be explained by this.
For mAb 39F, the sequence of the two viruses neutralized
(92BR020 and 93TH305) also correlated well with the mapping
results (Fig. 1); the presence of Ser at position 306 (virus 92BR020)
seems preferred over the smaller Gly (virus 93TH305). Of the 13
viruses resistant to neutralization by mAb 39F, the resistance of 6
viruses (BG1168, 5768-p27, 6101-p15, 92BR021, 92HT594, and ME1)
could be explained by alterations of residues important for binding
(Fig. 1), whereas neutralization of the 7 other viruses (QH0515,Fig. 1. Epitope speciﬁcity of V3 mAbs related to neutralizing activity. The V3 sequences of t
92BR021, multiple sequences are listed to represent the different V3 sequences that have be
quasispecies pools were used only a single sequence (shown) has been reported. To depict w
neutralization sensitivity; viruses not neutralized are ranked in the order as they appear in Tab
are colored as in Table 2; dashes indicate sequence homology with the virus that was neutrali
V3 sequence of the most potently neutralized virus are denoted by a dot. Sequence alignmen
and formatted for publication using the sequence alignment publishing tool SeqPublish (htQH0692, SS1196, 91US056, 92US712, JR-CSF, and JR-FL) could not be
accounted for by sequence incompatibility.
For the remaining 5 mAbs (CO11, F2A3, F530, LA21, and LE311) we
observed also that the V3 sequence of some viruses could not account
for neutralization resistance. Speciﬁcally, we observed that the V3
sequences of viruses QH0692, SS1196, 92US712, JR-CSF, and JR-FL
consistently could not account for neutralization resistance (Fig. 1). It
should be noted that all of these viruses are sensitive to neutraliza-
tion by V3 mAbs B4e8, 447-52D, and/or 58.2 (Binley et al., 2004;
Pantophlet et al., 2007), indicating that their V3 loop is not
inaccessible to antibody. We observed also that the V3 sequence of
other select viruses could not account for neutralization resistance of
some mAbs tested here, for example virus BG1168 for mAbs CO11 and
LE311, virus 91US056 for mAb LA21, and virus 6101-p15 for mAb
F530.
MAb ﬁne speciﬁcity mapped onto V3 in the structural context of gp120
To obtain a better understanding of the spatial organization of
residues identiﬁed here as important for V3 mAb binding, we
projected the results of the mapping onto the structure of a soluble
CD4-, Fab X5-complexed gp120 corewith the V3 loop attached (Huang
et al., 2005). We chose this structure because the conformation of the
V3 stem is not considered substantially inﬂuenced by interactions
with the antibody (Huang et al., 2005).he 15 subtype B viruses investigated in this study are shown. For viruses QH0515 and
en reported from quasispecies pools of these 2 viruses; for the other viruses for which
hich residues are most permissible for each mAb, viruses are ranked according to their
le 1. The locations of those residues that substantially diminish or enhancemAb binding
zed most potently and, to maintain clarity, are not colored. Sequence gaps relative to the
t was performed using ClustalW2 (http://www.ebi.ac.uk/clustalw/) (Larkin et al., 2007)
tp://www.hiv.lanl.gov/content/hiv-db/SeqPublish/seqpublish.html).
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we observed a distinct binding site formed by Arg304 in the N-terminal
V3 stem and Arg315, Phe317, and Tyr318 in the C-terminal half of the V3
tip. Pro313, which was also important for binding, is somewhat distant
from the distinctive formation of the other 4 residues, suggesting that
the primarily role of Pro313 is to properly juxtapose the residues that
form the 19b epitope, as suggested previously (Moore et al., 1995). The
side chain of Arg315 is not critical for 19b binding, given that efﬁcient
binding is also observed to monomeric gp120JR-CSF with a Gln
substitution at the same position (Pantophlet et al., unpublished
observations). Thus, the presence of both the Pro and Arg residues is
required to form the V3 tip hairpin turn and juxtapose the ‘true’
contact residues. Ile307 also lies somewhat distant from the epitope
map and at ﬁrst glance it would appear unlikely that this residue
interacts with mAb 19b directly. However, based on the substantial
decrease in 19b binding to I307A mutant, its presence seems crucial
for proper presentation of the epitope. This notion is supported by
previous results showing that mAb 19b prefers residues with aliphatic
side chains at position 307 (Moore et al., 1995).
Residues important for the binding of mAb 39F – Lys305, Ser306,
Ile307, and Ile309 – also form a distinct binding site on the N-terminal
ﬂank of V3, along the length of the V3 structure (Fig. 2), supporting the
notion that this antibody interacts with the N-terminal part of V3.
Projection of the Ala-scanning results for mAbs CO11, F2A3, LA21, and
LE311 onto the V3 structure shows that the epitope maps of mAbs
F2A3 and LE311 are similar to those of mAbs CO11 and LA21, most
notably His308, Pro313, and Arg315 (Fig. 2). However, the maps for CO11
and LA21 share a higher similarity than the maps for mAbs F2A3 and
LE311, which are more similar to each other. The maps for CO11 and
LA21 are somewhat similar to the map for mAb B4e8, with the notable
difference that B4e8 binding is not critically dependent on Pro313
(Fig. 2). Although the residues important for CO11 and LA21 binding
form a somewhat disjointed pattern, these mAbs likely also contact
neighboring residues. A similar disconnected pattern is observed with
residues important for the binding of mAb B4e8 (Fig. 2), yet structural
analysis later revealed that B4e8 forms less-critical interactions with
neighboring residues (Bell et al., 2008).
For mAbs F2A3 and LE311 we observed that Lys305, Ile307/His308,
and Pro313, all of which are important for mAb binding, form a nearly
linear arrangement on the V3 structure. In the case of mAb F2A3, the
location of residues that, upon substitution to alanine, increased
antibody binding are crowded around the 4-residue linear arrange-
ment, supporting the notion that residues at the adjacent positions
play a substantial role in the spatial positioning of the contact
residues.
For mAb F530 we obtained a map that resembled the maps
obtainedwithmAbs CO11, F2A3, LA21, and LE311 (Fig. 2). However, the
notable ability of mAb F530 to bind V3 without requiring the presence
of Arg315 suggests that this antibody, like mAb 39F, interacts mostly
with the N-terminal ﬂank of the V3 loop.
Discussion
Our results illustrate how the epitope ﬁne speciﬁcity of antibodies
to V3 may affect their level of cross-neutralizing activity. All 7 mAbs
tested here neutralized very few viruses; common among all mAbs
was the requirement for one or more positively-charged residues at
the juncture of the N-terminal ﬂank of the V3 stemwith the V3 tip for
efﬁcient binding. The mAbs also depended, to varying extents, on the
presence of the Pro at the V3 tip for efﬁcient binding. We posit that
the requirement for interaction with certain residues near the V3
stem and in the V3 tip angles the mAbs such that they are restricted
from interacting with their cognate epitope on many viruses,
exempliﬁed here by viruses QH0692, SS1196, 92US712, JR-CSF, and
JR-FL. These 5 viruses do not have alterations in residues identiﬁed by
our scanning mutagenesis approach as being important for bindingbut nevertheless were not neutralized by the 7 mAbs that were studied
here. However, we know that the V3 loops on these viruses are not
completely inaccessible to antibody, given that theseviruses are sensitive
to neutralization by V3 antibodies such as B4e8 and 447-52D.
The factor(s) responsible for restricting V3 access of the 7 mAbs
tested here remain to be identiﬁed. Recent studies using chimeric
viruses have shown that the V1/V2 loop on some primary viruses, e.g.
JR-FL an YU2,may greatly restrict antibody access to V3 (Krachmarov et
al., 2005, 2006; Pinter et al., 2004). It is therefore tempting to speculate
that V1/V2 may also be limiting V3 access on the other viruses tested
here but thiswill need to bedeterminedexperimentally; for example, it
is conceivable that speciﬁc residues outside of V3 (and V1/V2) affect
the presentation of V3 antibody epitopes. It should be noted that we
did not investigate further the relative importance of residues
identiﬁed as critical for antibody binding in the context of different
V3 sequences. It is possible that the contribution of each residue to
binding afﬁnitymay vary in the context of V3 sequences from different
viruses. More detailed studies, for example, by investigating changes
in the sensitivity of neutralization-resistant viruses used here inwhich
residues in V3 important antibody binding are introduced may help to
further elucidate the relationship between sequence variability and
neutralization sensitivity.
Only structural information can provide accurate insight into how
the 7 mAbs tested here interact with V3. Nevertheless, even in the
absence of such information, we believe structural information from
other V3 mAbs for which important binding residues have been
determined supports the hypothesis that binding speciﬁcity may
greatly affect the level of antibody access to V3. For example, mAbs
59.1 (epitope: 306RIHIGPGRAFYTT320), 50.1 (epitope: 305KRIHIGP313),
83.1 (epitope: 306RIHIGPGR315), and 58.2 (epitope: 306RIHIGP-
GRAFY
318
) bind overlapping epitopes on V3 (Seligman et al., 1996)
and requiremany of the same residues for efﬁcient binding (important
contact residues are underlined; critical residues are double under-
lined (White-Scharf et al., 1993)). Nonetheless, these 4 mAbs interact
from markedly different angles with V3 (Fig. 3). MAbs 59.1, 50.1, and
83.1, which only neutralize viruses that are generally sensitive to
antibody neutralization (Bou-Habib et al., 1994), seem to require a
particular β hairpin turn conformation at the center of the V3 tip
(GPGR) for binding, as judged by the substantial reduction in binding
efﬁciency upon substituting one or both glycine residues. This hairpin
turn requirement mirrors the strong dependence of mAbs 19b, LE311,
CO11, and LA21 on the presence of the proline in the GPGR turn for
binding, presumably to juxtapose important contact residues. Thus,
mAbs 19b, LE311, CO11, and LA21 may need to interact with V3 from
angles, perhaps similar to mAbs 59.1, 50.1, and/or 83.1, which do not
permit access to V3 on many different primary viruses. MAb 58.2,
which neutralizes a few more primary viruses than mAbs 19b, LE311,
CO11, or LA21 (Table 1; (Binley et al., 2004)), seems less dependent on
the precision of the turn given that its binding is only substantially
diminished upon substituting Arg315 (White-Scharf et al., 1993), and
interacts with V3 from an angle that is notably different from mAbs
59.1, 50.1, and 83.1 (Fig. 3).
The association of low cross-neutralizing activity with binding to
the residues in or near the V3 stem segment is supported by other
observations. For example, it has been shown that isolate-speciﬁc V3
responses in subtype B- and D-infected individuals are directed to
residues located in the stem segments of the V3 loop (Lawoko et al.,
2000; Schreiber et al., 1997) and weakly neutralizing serum antibody
responses to V3 in individuals immunized with recombinant gp160
are preferentially directed to the N-terminal stem of V3 (Coefﬁer et al.,
1997). Furthermore, in a recent study seeking to elicit 447-52D-like
NAbs by utilizing fusion proteins containing the 447-52D contact
epitope 305KSIHIGPGRAFYTT320 (Chakraborty et al., 2006), immune
sera seemed to require for binding the N-terminal segment of the
engrafted motif and neutralized the generally-sensitive virus MN but
not the more resistant viruses BaL or JR-FL.
Fig. 3. Angle of interaction between V3 antibodies and V3. Structure of gp120JR-FL-core containing V3 (Huang et al., 2005) (purple; ribbon representation) shown from 3 perspectives
with the Fab fragments of 7 different mAbs (surface rendering) superimposed to depict their different angles of interactionwith V3. (A) Gp120 from the perspective of CD4; (B) Gp120
from the perspective of gp41 and the gp120:gp41 interface; (C) Gp120 from the approximate perspective of a coreceptor molecule (e.g. CCR5). To establish the angle for eachmAb, the
V3 peptide (not shown for clarity purposes) from each mAb:peptide complex structure was superimposed onto the V3 structure of gp120 using the MatchMaker feature in UCSF
Chimera, which constructs a sequence alignment and then performs a least-squares ﬁt to superimpose the aligned residue pairs; the sequence alignment is based on a combination of
residue identity/similarity and secondary structure correspondence. The V3 mAbs shown are: B4e8 (red), 447-52D (blue), 58.2 (magenta), 59.1 (grey), 50.1 (cyan), 83.1 (yellow), and
2219 (green). Aside from V3, additional regions of gp120 (N- and C termini, V1/V2 stem, and V4) are denoted to orientate the reader.
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neutralize several primary viruses (Binley et al., 2004; Pantophlet et
al., 2007), interact with V3 within nearly the same plane of
orientation; antibodies interacting with V3 from other angles tend
to exhibit lower cross-neutralizing activity (Bou-Habib et al., 1994;
Gorny et al., 2004; York et al., 2001). The importance of the angle of
antibody interaction for effective neutralization of HIV is exempliﬁed
by insight from recent crystal structures of the broadly neutralizing
mAbs 2F5, 4E10, and b12 in complex with antigen (Cardoso et al.,
2005; Zhou et al., 2007), which suggest that such antibodies need to
interact with their target sites from speciﬁc angles to gain access to
their epitopes on infectious virions; the difﬁculty in eliciting 2F5-,
4E10-, and b12-like antibodies supports the notion that these sites are
not easily accessed. Our results illustrate how similar restrictive
factors might apply to V3 antibodies. MAb 58.2 exhibits the lowest
cross-neutralizing activity among the 3 mAbs that neutralize several
primary viruses, despite interacting with V3 from nearly an identical
angle as mAb 447-52D. This difference in neutralizing activity may be
due to mAb 447-52D forming main-chain contacts with residues in
the V3 stem region, which has been suggested to enhance its ability to
neutralize a notable fraction of viral isolates (Stanﬁeld et al., 2004).
MAb B4e8, which seems to neutralize slightly better than mAb 447-
52D (Keele et al., 2008; Pantophlet et al., 2007), interacts with V3 from
a slightly elevated angle relative to the 2 other mAbs.
In sum, we have presented here an extensive analysis in an attempt
to better understand how epitope ﬁne speciﬁcity affects the
neutralizing activity of V3 antibodies. Previous studies have shown
that V3 may be shielded by the V1/V2 region (Cao et al., 1997;
Krachmarov et al., 2006; Pinter et al., 2004; Wyatt et al., 1993), but
such studies provided little explanation for the spectrum of sen-
sitivities exhibited by a given primary isolate to the neutralizingactivity of different V3 mAbs. Antibodies that interact with V3 from
certain angles may indeed be greatly restricted from accessing their
epitope on several viruses, depending on the stringency of the steric
constraints. However, certain parts of V3 may still be accessible to
antibody from select angles. The V3 tip in particular seems somewhat
better accessible on different viruses, as judged from the appreciable
neutralizing activity exhibited by mAb B4e8 (Pantophlet et al., 2007).
The apparently unique binding mode of mAb B4e8, and potentially
those of other V3mAbs (Gorny et al., 2006), may provide an avenue for
further investigations into V3 tip accessibility on different viruses, for
example by engineering variants with speciﬁcities for V3 sequences
not recognized by the parental antibody.
Materials and methods
Antibodies
Seven human mAbs directed to the V3 loop on HIV-1 gp120 were
studied here: 19b, 39F, CO11, F2A3, F530, LA21, and LE311. MAb 19bwas
isolated fromanasymptomatic individual infectedwith a cladeBvirusby
Ebstein–Barr virus (EBV) transformation of peripheral blood lympho-
cytes and was shown to be speciﬁc for the V3 loop by mapping with
peptides (Scott et al., 1990). MAbs 39F and F2A3 were isolated from two
subtypeB-infected long-termnon-progressors andmAbsCO11, LA21and
LE311were isolated from three different patients (AC-01, AC-05, and AC-
033, respectively) on anti-retroviral therapy during acute infection who
then underwent several periods of structured treatment interruptions
(Monteﬁori et al., 2001; Rosenberg et al., 2000). These mAbs were
selected as described elsewhere (Xiang et al., 2003) and have been
deﬁned as beingdirected to V3 based on their reactivitywith select clade
B V3 peptides (J. Robinson, unpublished data). MAb F530 was isolated
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splenocytes with HMMA human myeloma cells (Posner et al., 1989,
1987). Hybridomas were selected based on speciﬁc reactivity of
hybridoma supernatants with HIV-infected cells and ability of the
antibodies to capture a relatively high degree of virions in a virus capture
assay (L. Cavacini, unpublished results). The general speciﬁcity of mAb
F530 for the V3 loop was determined based on its binding proﬁle with
variable-loop deleted gp120 mutants (L. Cavacini, unpublished results).
Most mAbs described above have been utilized in previous antigen
binding studies and were selected for study here based on their overall
broad reactivity with envelope-based preparations from different clade
B viruses and consensus sequences (Grundner et al., 2002; Haynes et al.,
2006;Kochet al., 2003; Liaoet al., 2006;Moore et al.,1994; Pantophlet et
al., 2004; Patel et al., 2008; Selvarajah et al., 2005; Yang et al., 2002).
Viruses
Pseudovirus preps were produced by co-transfection of HEK293
cells with an env-expressing plasmid (pCXAS) and a subgenomic
plasmid (pHIVlucΔU3) as describedpreviously (Binleyet al., 2004). The
test viruses (n=15; Table 1) were selected from a 30-member panel of
subtype B primary viruses used in a previous study by Binley et al.
(Binley et al., 2004). Eight of the test viruses were quasispecies derived
from primary virus cultures and are as follows: QH0515 (Binley et al.,
2004; Cleghorn et al., 2000; Hu et al., 2000; Li et al., 2005), QH0692
(Binley et al., 2004; Cleghorn et al., 2000; Li et al., 2005), 5768-p27
(Binleyet al., 2004; Li et al., 2005), 6101-p15 (Binleyet al., 2004; Li et al.,
2005), 91US056 (Binley et al., 2004; Trkola et al., 1995), 92BR021
(Binley et al., 2004; Gao et al.,1994; Torre et al., 2000), 93TH305 (Binley
et al., 2004), and ME1 (Binley et al., 2004; Chen et al., 1997); the noted
references are for env sequences belonging to these viruses that have
been reported in the Binley et al. study and elsewhere. The remaining 7
viruses were molecular clones. Three of these molecular clones
(92HT594, JR-CSF, and JR-FL) have been described previously (Binley
et al., 2004), whereas the remaining four clones (BG1168, SS1196,
92BR020, 92US712) have not been reported previously; each mole-
cular clone was selected from a panel of 6 clones derived from the
respective viral quasispecies pools reported previously (Binley et al.,
2004). Each clone was chosen based on the overall similarity between
its sensitivity to neutralization by the broadly neutralizing mAbs b12,
2G12, 2F5, and 4E10, and a broadly neutralizing HIV+ serum and the
neutralization sensitivity proﬁle of the corresponding viral quasispecies
to the same inhibitors (T. Wrin et al., unpublished results).
Neutralization assays
Neutralization assays were performed at Monogram Biosciences
utilizing high-throughput neutralization assay systemwith U87 target
cells expressing CD4, CCR5, and CXCR4 and pseudotyped viruses
(Richman et al., 2003; Schweighardt et al., 2007). Assay conditions
were the same as described previously (Binley et al., 2004); serial
dilutions of mAb, starting at 50 μg/ml, were incubated for 1 h with
virus after which the mixture was added to target cells.
Generation of V3 mutants
The V3mutants, generated in the JR-CSF background, were the same
as described recently for mapping the epitope speciﬁcity of mAb B4e8
(Pantophlet et al., 2007).AllmutationswereveriﬁedbyDNAsequencing.
Epitope mapping by ELISA
Binding assays to determine apparent antibody binding afﬁnities
were performed using viral lysates of supernatants collected from
transiently-transfected 293Tcells as described (Pantophlet et al., 2007,
2003). The mAbs were added to the ELISA plate wells in 5-fold serialdilutions and binding was detected with a peroxidase-conjugated
secondary antibody and TMB substrate (Pierce). Apparent binding
afﬁnities (Kapp) were deﬁned as the antibody concentrations at half-
maximal binding; percentage changes in afﬁnity relative to wild-type
gp120 were calculated as: [Kapp wild-type/Kapp mutant]×100%.
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